Treace Announces Clinical Study Data Demonstrating Positive Lapiplasty® and Adductoplasty® Outcomes at the 2025 ACFAS Annual Scientific Conference

Core Insights - Treace Medical Concepts, Inc. presented updated interim data for its clinical studies on Lapiplasty and Adductoplasty procedures at the 2025 ACFAS Annual Meeting, highlighting positive clinical outcomes and the differentiation of these procedures in the market [1][2]. Clinical Study Summaries - ALIGN3D™ Lapiplasty Clinical Study: The interim analysis included 135 of 173 patients with at least four years of follow-up, showing low radiographic recurrence rates of 0.8% using HVA>20° and 7.7% using HVA>15° at 48 months, along with significant improvements in pain and patient-reported outcomes [3][6]. - Mini3D™ Lapiplasty Mini-Incision™ Clinical Study: The study involved 75 of 105 patients with at least one year of follow-up, reporting early return to protected weightbearing at an average of 7.9 days and low recurrence rates of 0.0% using HVA>20° and 5.5% using HVA>15° at 12 months [4][7]. - MTA3D™ Adductoplasty Clinical Study: This study included 18 of 38 patients with at least one year of follow-up, showing early return to protected weightbearing at an average of 7.5 days and clinically significant improvements in pain and patient-reported scores at 12 months [5][8]. Company Overview - Treace Medical Concepts is focused on advancing surgical management for bunions and related midfoot deformities, with an estimated 1.1 million annual surgical candidates in the U.S. [15][16]. The company has developed the Lapiplasty 3D Bunion Correction System and the Adductoplasty Midfoot Correction System to address these conditions [15][16].